Skip to main content
. Author manuscript; available in PMC: 2015 Feb 7.
Published in final edited form as: J Theor Biol. 2013 Oct 23;342:15–22. doi: 10.1016/j.jtbi.2013.10.006

Table 1. Epidemiological parameters.

These parameters value were used in the analysis unless indicated otherwise.

Symbol Parameter Value (references)
bm Birth rate of mosquitoes *Calibrated for constant population*
dO Death rate of mosquitoes 0.042 d−1 (4448)
bh Birth rate of humans *Calibrated for constant population*
dh Death rate of humans 0.0000165 d−1 (49)
χ Proportion of dengue infections that are symptomatic 0.2 (28, 50, 51)
ε Rate of loss of maternal antibodies 0.0075 d−1 (52, 53)
δ Rate of loss of cross-immunity 0.0055 d−1 (4, 24, 28)
γ Dengue fever (non-DHF) recovery rate 0.1429 d−1 (28, 52, 53)
η1 Rate of developing DHF after primary infection 0.002 d−1 (8)
η2 Rate of developing DHF after secondary/tertiary/quaternary infection Age-dependent data (31)
α Risk of death from DHF 0.01 (54)
φ DHF recovery rate 0.2 d−1 (52)
c Biting rate (number of bites per mosquito per day) 0.7 bitesmosquitoes*d (55)
σi Relative probability of being susceptible to new infection after having i previous infections
1i4
β0 Percentage of human infected per bite 0.5 humanbite (53, 56)
βm Percentage of mosquito infected per bite 0.9 mosquitobite (53, 56)
κouta
Rate of aging out of age group a Proportional to the length of age group a
κIna
Rate of aging into age group a Proportional to the length of age group a−1
πa Age-dependent relative probability of mosquito-to-human transmission Thailand: πa = 1; Brazil: π1 = 0.1, π2 = 0.2, π3 = 0.3, π4 = 0.8, πj = 1, j = 5,6,7.
*Calibrated to fit DHF profiles*
Pvaca
Proportion of vaccinated individuals in age group a Varied
Veff Vaccine efficacy 0.75